OakChart

Silence Therapeutics Plc ADR

SLNHealthcare·Biotechnology·United Kingdom·Small·NASD·Nov 11 • 12:54 PM ET

19.77-0.02 (-0.09%)
2026-11-11 18:54 CET
Market cap
1,230.03 USD m
Revenue, TTM
0.61 USD m
Net income, TTM
-59.80 USD m
Free cash flow, TTM
-42.12 USD m
EPS diluted, TTM
-1.27
P/E
-
Compare

Price

SLN against its 20, 50 and 200-day averages
2050200beat
5.0010.0015.0020.0036.0M71.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SLNclose 19.7720-day 18.6650-day 14.46200-day 9.6319.77

0.5% under the 52-week high of 19.87 on 26 Oct 2026. 52-week low 4.19 on 12 Feb 2026. Last 15 sessions, 1.2% high to low

Profile

SLN
52-week range, 99% of the way up
4.1919.86

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Employees88
IPOSep 08, 2020
Beta1.35
ATR, 14d0.45
Rel volume0.11
Short float4.66%
Insider own16.46%
Inst own27.43%

Snapshot

6 groups

Valuation

Index-
Market Cap1.23B
Enterprise Value1.16B
Income-59.80M
Sales0.61M
Book/sh0.81
Cash/sh1.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees88
IPOSep 08, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S2014.54
P/B24.28
P/C17.06
P/FCF-
EV/EBITDA-
EV/Sales1896.60
Quick Ratio7.42
Current Ratio7.42
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.27
EPS next Y-0.55
EPS next Q-0.11
EPS this Y42.06%
EPS next Y-51.23%
EPS next 5Y-1.68%
EPS past 3/5Y-6.68% -4.20%
Sales past 3/5Y-70.38% -39.70%
EPS Y/Y TTM24.26%
Sales Y/Y TTM-
EPS Q/Q55.62%
Sales Q/Q-100.00%
EarningsAug 10 BMO
EPS/Sales Surpr.35.11% -91.44%

Ownership

Insider Own16.46%
Insider Trans0.00%
Inst Own27.43%
Inst Trans13.87%
ROA-44.03%
ROE-90.18%
ROIC-155.41%
Gross Margin15.82%
Oper. Margin-10478.17%
Profit Margin-9751.68%
SMA205.98%
SMA5036.70%
SMA200105.35%
Trades-

Technical

Shs Outstand62.15M
Shs Float51.92M
Short Float4.66%
Short Ratio0.95
Short Interest2.42M
52W High19.86 -0.47%
52W Low4.19 371.90%
Volatility0.33% 1.65%
ATR (14)0.45
RSI (14)78.03
Beta1.35
Rel Volume0.11
Avg Volume2.55M
Volume155,107

Performance

Perf Week-0.14%
Perf Month122.92%
Perf Quarter41.54%
Perf Half Y183.28%
Perf YTD225.21%
Perf Year194.24%
Perf 3Y114.92%
Perf 5Y-14.77%
Perf 10Y-
Recom2.60
Target Price20.00
Prev Close19.79
Price19.77
Change %-0.09%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jun 24, 2026InitiatedCCantor FitzgeraldOverweight
Feb 11, 2025InitiatedGGoldmanSell$6-69.7%
Dec 02, 2024ReiteratedBBMO Capital MarketsOutperform
Sep 03, 2024InitiatedJJefferiesBuy$40+102.3%
Jan 31, 2024InitiatedBBMO Capital MarketsOutperform$67+238.9%

Peers

Mkt cap
TickerCompanyMkt cap
ARWRArrowhead Pharmaceuticals Inc6.93B
ALNYAlnylam Pharmaceuticals Inc21.05B
IONSIonis Pharmaceuticals Inc4.84B
SCTXScribe Therapeutics Inc331.30M
PTGXProtagonist Therapeutics Inc8.70B
WVEWave Life Sciences Inc680.62M
ABUSArbutus Biopharma Corp763.69M
NAMSNewAmsterdam Pharma Company NV2.45B
ARCTArcturus Therapeutics Holdings Inc266.32M
AMGNAMGEN Inc250.24B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
ARBAltShares Merger Arbitrage ETFAUM: 110.88M
MNANYLIM Merger Arbitrage ETFAUM: 263.22M
HXAMast HedgeIndex Corporate Arbitrage ETFAUM: 52.04M
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
APIEActivePassive International Equity ETFAUM: 1.13B
EVNTAltShares Event-Driven ETFAUM: 13.33M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 166
  • Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 (Business Wire)
  • Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
  • Silence Therapeutics Agrees to $1.3 Billion Merck KGaA Acquisition at 130% Premium (InvestorsHub) +125.58%
  • Silence Therapeutics jumps 59% on Merck takeover (Proactive)
  • Loading…
  • Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech (Barrons.com)
  • Silence Therapeutics stock soars 125% on Merck acquisition (Investing.com)
  • Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany (Business Wire)
  • Silence Therapeutics to Participate in Three September Investor Conferences (Business Wire)
  • Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs (Business Wire)
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile (Business Wire) +29.12%
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results (Business Wire)
  • Silence Therapeutics shares surge ahead of divesiran Phase 2 results call (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-10-0.090-0.139-0.0900.101.177
2026Q12026-05-07-0.110-0.129-0.3160.421.256
2025Q42026-03-05-0.090-0.186-0.2490.042.916
2025Q32025-11-06-0.150-0.187-0.4410.164.385
2025Q22025-08-07-0.190-0.133-0.5860.227.034
2025Q12025-05-08-0.200-0.151-0.6060.145.206
2024Q42025-02-270.070-0.2140.09025.426.836
2024Q32024-11-14-0.243-0.127-0.7461.455.675
2024Q22024-08-15-0.142-0.115-0.4200.7711.854
2024Q12024-05-16-0.018-0.119-0.05415.746.414
2023Q42024-03-13-0.159-0.081-0.4512.698.886
2023Q32023-11-14-0.091-0.168-0.2803.432.914
2023Q22023-08-16-0.122-0.177-0.36011.573.924
2023Q12023-05-16-0.118-0.150-0.34514.183.143
2022Q42023-03-150.452-0.012-0.44917.8320.372
2022Q32022-11-10-0.084--0.2543.94--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.986-0.767-0.9980.312.28
2020FY-1.637-0.754-1.5317.5112.49
2021FY-0.583-1.073-1.82816.3420.14
2022FY-0.510-0.434-1.54921.2928.56
2023FY-0.498-0.442-1.46832.4736.08
2024FY-0.330-0.722-0.98043.2625.04
2025FY-0.630-0.907-0.6300.567.88
2026FY--0.365--0.44
2027FY--0.552--1.26
2028FY--0.662--0.71
2029FY--0.620--0.00
2030FY--0.435--100.6

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-275000.110.000.40
2026Q3S2026-10-245010.110.000.40
2026Q3S2026-08-136020.120.000.40
2026Q3S2026-08-106011.120.006.00
2026Q3S2026-07-216001.140.006.00
2026Q3S2026-06-236201.140.006.00
2026Q3S2026-06-105201.370.106.00
2026Q3S2026-05-075201.370.106.00
2026Q3S2026-03-055021.260.006.00
2026Q3S2026-02-035001.420.106.00
2026Q3S2026-01-224001.720.106.00
2026Q3S2025-12-243000.290.100.61
2026Q3S2025-11-114001.720.106.00
2026Q3S2025-11-104001.720.106.00

Estimate history

EPS, annual-0.089-1.047-0.998-1.531-1.828-1.549-1.468-0.98-1.881-1.2661
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.054-0.42-0.746-0.606-0.586-0.441-0.249-0.316-0.26
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.02100.3117.02617.07421.55731.76643.2760.560.61
Period201720182019202020212022202320242025TTM
Sales, quarterly15.730.7551.4850.1430.2270.1580.0340.4210
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.33123.6926.12327.76929.92835.93639.61647.22547.23447.246
Period201720182019202020212022202320242025MRQ
Shares, quarterly46.57646.79847.21547.2347.23447.23447.23447.23547.246
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.610.5643.2831.7721.5617.077.030.310.00
Cost of Goods Sold Incl. D&A0.520.6212.0713.1714.0010.845.46-0.53
Gross Profit0.10-0.0631.2018.607.566.231.57--0.53
Selling, General and Administrative Excl. Other64.3582.4380.8171.2367.4269.2443.2128.7026.89
Research and Development43.4160.4354.1745.1643.8542.2925.8916.9712.96
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-64.26-82.48-49.60-52.64-59.86-63.01-41.65-29.00-27.42
Interest Expense0.000.000.000.000.060.010.020.040.00
Unusual Expense0.001.330.000.000.000.00-1.91--
Net Income Before Taxes-59.80-88.81-44.48-53.48-58.35-63.07-46.22-29.18-27.37
Income Taxes0.000.010.850.96-8.47-8.87-4.48-4.19-2.82
Consolidated Net Income-59.80-88.82-45.33-54.44-49.87-54.20-41.74-24.98-24.55
Net Income From Continuing Operations-59.80-88.82-45.33-54.44-49.87-54.20-41.74-24.98-24.55
Net Income-59.80-88.82-45.33-54.44-49.87-54.20-41.74-24.98-24.55
EPS (Recurring)-1.27-1.86-0.98-1.47-1.55-1.83-1.58-1.00-1.05
EPS (Basic, Before Extraordinaries)-1.27-1.88-0.98-1.47-1.55-1.83-1.53-1.00-1.05
EPS (Diluted)-1.27-1.88-0.98-1.47-1.55-1.83-1.53-1.00-1.05
EBITDA-63.78-81.93-49.01-52.01-59.26-62.42-41.01-28.39-26.89
Non-Operating Income (Expense)4.46-5.005.12-0.841.57-0.05-6.46-0.130.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-6.3912.8912.9110.239.624.570.600.74
Price To Sales Ratio845.75512.527.3520.2822.7841.4985.35--
Gross Margin15.82-9.8472.1058.5435.0836.5022.29--
Operating Margin-10,478.17-14,720.94-114.62-165.70-277.66-369.02-592.77-9,316.40-
Net Margin-9,751.68-15,851.89-104.74-171.37-231.35-317.44-594.03-8,025.42-
Shares Outstanding47.2547.2347.2239.6235.9429.9327.7726.1223.69
Market Capitalization1,230.031,230.03324.84671.70456.40714.98610.91604.08-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q2
Total Revenue0.000.420.030.160.230.141.480.75
Cost of Goods Sold Incl. D&A0.110.120.110.180.190.163.613.33
Gross Profit-0.110.30-0.08-0.020.03-0.01-2.12-2.57
Selling, General and Administrative Excl. Other13.0015.3312.5323.4920.5525.8227.1820.55
Research and Development8.318.348.9117.8515.4718.2019.9013.87
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.11-15.02-12.61-23.51-20.52-25.83-29.30-23.12
Interest Expense0.000.000.000.000.000.0011.180.23
Unusual Expense0.000.000.000.001.340.000.000.00
Net Income Before Taxes-12.29-14.93-11.75-20.83-27.68-28.64-39.21-22.01
Income Taxes0.000.000.000.000.010.00-4.09-2.37
Consolidated Net Income-12.29-14.93-11.75-20.83-27.69-28.64-35.12-19.64
Net Income From Continuing Operations-12.29-14.93-11.75-20.83-27.69-28.64-35.12-19.64
Net Income-12.29-14.93-11.75-20.83-27.69-28.64-35.12-19.64
EPS (Recurring)-0.26-0.32-0.25-0.44-0.57-0.61-0.75-0.42
EPS (Basic, Before Extraordinaries)-0.26-0.32-0.25-0.44-0.59-0.61-0.75-0.42
EPS (Diluted)-0.26-0.32-0.25-0.44-0.59-0.61-0.75-0.42
EBITDA-13.00-14.91-12.50-23.36-20.37-25.69-29.15-22.97
Non-Operating Income (Expense)0.820.090.862.69-5.82-2.811.281.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.042.44-1.991.672.812.903.10
Price To Sales Ratio845.75296.33511.66---41.5939.24
Gross Margin-72.27-232.35-12.8914.06-9.51-142.91-341.14
Operating Margin--3,565.40-37,149.87-14,881.15-9,048.19-18,119.74-1,973.47-3,064.05
Net Margin--3,544.31-34,617.52-13,181.15-12,211.58-20,091.58-2,365.32-2,602.34
Shares Outstanding47.2547.2347.2347.2347.2347.2347.2146.80
Market Capitalization1,230.03248.92287.18245.14273.94133.17850.78884.94

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments85.11147.3368.7985.5899.6051.1944.4033.8058.25
Short Term Receivables24.6126.9123.9820.8611.5045.824.663.122.66
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets8.9313.1210.389.865.847.430.570.660.70
Total Current Assets118.66187.37103.15116.30116.93104.4349.6337.5761.61
Net Property, Plant & Equipment1.751.982.312.652.631.540.811.171.58
Total Investments and Advances0.000.000.000.340.410.410.360.350.00
Long-Term Note Receivable-------0.000.32
Intangible Assets10.919.7010.3410.0210.3211.1310.2410.4310.90
Other Assets0.133.593.650.000.000.000.000.000.00
Total Assets131.44202.63119.45129.31130.29117.5261.0449.5274.41
Short Term Debt Incl. Current Port. of LT Debt0.090.120.230.540.190.470.380.000.00
Accounts Payable4.413.703.353.835.513.122.371.460.62
Income Tax Payable0.040.650.470.710.25-0.000.03-
Other Current Liabilities9.0812.3618.2921.3214.6031.3710.043.382.97
Total Current Liabilities13.6116.8222.3426.4020.5434.9612.794.883.59
Long Term Debt0.070.000.120.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities55.4551.7975.0076.3798.2070.1820.550.000.00
Total Liabilities69.1468.6197.46102.76118.74105.1333.344.883.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity62.30134.0221.9926.5511.5512.3827.7044.6570.82
Total Shareholders Equity62.30134.0221.9926.5511.5512.3827.7044.6570.82
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity62.30134.0221.9926.5511.5512.3827.7044.6570.82
Total Liabilities & Stockholders Equity131.44202.63119.45129.31130.29117.5261.0449.5274.41
Book Value Per Share1.322.840.560.740.390.451.061.883.04
Tangible Book Value Per Share1.092.630.290.460.040.050.671.442.57
Full-Time Employees8811610912210574---
Price to Book Ratio24.302.5627.5214.3721.8649.3317.70--
Return on Assets-53.17-28.13-43.77-38.42-43.74-46.75-45.19-39.62-2.91
Return on Equity-90.48-58.20-224.29-261.81-452.97-208.25-69.06-42.52-3.02
Return on Invested Capital-142.40-33.82-246.20-187.84-469.35-337.04-90.19-54.99-2.94
Quick Ratio8.7211.144.624.415.692.993.887.7017.14
Current Ratio8.7211.144.624.415.692.993.887.7017.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-59.67-88.82-45.33-54.44-58.35-63.07-46.22-29.18-27.37
Depreciation0.480.560.590.620.590.590.640.610.53
Other Funds (Non Cash)2.8215.6610.1019.4611.9718.438.003.863.32
Funds from Operations-56.37-72.60-34.63-34.35-45.79-44.05-37.58-24.70-23.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital14.2610.18-33.04-15.30-10.1853.4223.9226.851.22
Cash from Operating Activities-42.11-62.42-67.67-49.65-55.969.37-13.652.14-22.30
Capital Expenditures-0.00-0.06-0.21-0.06-0.54-1.83-0.66-0.01-0.25
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments73.16-48.050.000.00-19.8613.7512.82-19.14-6.24
Purchase of Investments-158.15-166.800.000.00-19.860.000.00-19.14-6.67
Sale Or Maturity of Investments231.31118.750.000.000.0013.7512.820.000.43
Other Uses0.000.00-139.23-25.870.000.000.000.000.00
Other Sources0.000.00117.4645.300.000.00-0.00-
Cash from Investing Activities73.16-48.10-21.9819.37-20.4011.9212.17-19.15-6.49
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.02142.1532.0653.2642.5320.306.730.45
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.02142.1532.0653.2642.5320.306.730.45
Proceedsfrom Stock Options0.000.02142.1532.0653.2642.5320.306.730.45
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.000.02142.1532.0653.0342.2419.786.730.45
Exchange Rate Effect-0.320.200.060.750.28-0.14-0.430.05-0.00
Net Change in Cash30.73-110.3152.562.53-23.0663.3917.87-10.23-28.34
Free Cash Flow-42.12-62.47-67.88-49.71-56.147.57-14.312.13-22.47
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----93.56---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments72.0570.0885.11102.19114.16136.53
Short Term Receivables9.2922.2224.6122.1820.0416.84
Inventories0.000.000.000.000.000.00
Other Current Assets12.9410.568.939.2614.3616.42
Total Current Assets94.28102.85118.66133.63148.55169.79
Net Property, Plant & Equipment1.441.541.751.851.831.80
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets10.5610.6110.9110.9110.9310.09
Other Assets0.130.130.130.403.913.61
Total Assets106.41115.12131.44146.79165.23185.30
Short Term Debt Incl. Current Port. of LT Debt0.100.090.090.090.000.06
Accounts Payable12.6110.3713.3616.9914.3118.81
Other Current Liabilities-0.00-0.000.170.300.460.39
Total Current Liabilities12.7110.4613.6117.3814.7719.26
Long Term Debt0.010.040.070.100.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities55.2255.2255.4555.2556.3153.29
Total Liabilities67.9465.7269.1472.7371.0872.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity38.4749.4062.3074.0694.16112.74
Total Shareholders Equity38.4749.4062.3074.0694.16112.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity38.4749.4062.3074.0694.16112.74
Total Liabilities & Stockholders Equity106.41115.12131.44146.79165.23185.30
Book Value Per Share0.811.051.321.571.992.39
Tangible Book Value Per Share0.590.821.091.341.762.17
Full-Time Employees--88---
Price to Book Ratio24.304.003.882.602.431.05
Return on Assets-44.03-50.07----
Return on Equity-90.18-92.76----
Return on Invested Capital-31.94-30.20-18.84-28.08-29.41-25.40
Quick Ratio7.429.838.727.6910.068.81
Current Ratio7.429.838.727.6910.068.81

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-12.29-14.93-11.70-20.75-27.72-28.64
Depreciation0.110.110.110.160.150.14
Other Funds (Non Cash)0.911.90-0.760.7710.045.61
Funds from Operations-11.27-12.93-12.35-19.83-17.54-22.89
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital12.77-2.65-4.929.07-4.4910.53
Cash from Operating Activities1.49-15.58-17.27-10.76-22.03-12.36
Capital Expenditures0.000.000.00-0.00-0.05-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments64.949.98-53.4751.71-46.290.00
Purchase of Investments-0.10-64.32-73.83-19.90-73.070.00
Sale Or Maturity of Investments65.0474.3020.3671.6026.790.00
Other Uses0.000.000.000.0070.33-70.33
Other Sources0.000.000.000.00-25.7825.78
Cash from Investing Activities64.949.98-53.4751.70-1.79-44.55
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-0.00-0.000.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-0.00-0.000.000.01
Proceedsfrom Stock Options0.000.00-0.00-0.000.000.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.00-0.00-0.000.000.01
Exchange Rate Effect-0.06-0.02-0.13-0.110.200.23
Net Change in Cash66.38-5.61-70.8740.83-23.61-56.66
Free Cash Flow1.49-15.58-17.27-10.76-22.08-12.36

Revenue breakdown

Research Collaboration Income2024: 43.11M 2025: 559.00K
Royalty Income2024: 144.00K
Germany2024: 144.00K
United Kingdom2024: 43.11M 2025: 559.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.66%2.4M51.9M2.73M
2026-10-155.64%2.9M51.9M1.19M
2026-09-304.89%2.5M51.9M1.07M
2026-09-154.20%2.2M51.9M1.06M
2026-08-314.69%2.4M51.9M951.50K
2026-08-146.16%2.4M39.5M879.22K
2026-07-314.61%1.8M39.9M421.59K
2026-07-153.95%1.6M39.9M390.76K
2026-06-304.35%1.7M39.9M382.40K
2026-06-155.18%2.1M39.9M321.50K
2026-05-295.16%2.1M39.9M336.29K
2026-05-154.98%2.0M39.9M323.08K
2026-04-305.56%2.2M38.8M329.34K
2026-04-155.36%2.1M38.8M306.27K
2026-03-314.73%1.8M38.8M292.33K
2026-03-134.46%1.7M38.8M274.55K
2026-02-274.01%1.6M38.8M278.23K
2026-02-134.00%1.6M38.8M298.21K
2026-01-303.64%1.4M37.8M292.51K
2026-01-153.01%1.3M44.1M279.46K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5015.0019.900.000.0000.000.000.995-0.0180.000
call5.0012.5017.400.0014.0960.000.000.991-0.0180.001
call7.5010.0014.900.009.8630.000.000.987-0.0180.001
call10.009.7012.500.407.6441240.000.982-0.0180.001
call12.505.009.800.005.7050.000.000.975-0.0170.002
call15.004.707.504.104.4606.000.000.963-0.0160.003
call17.502.252.402.200.6483040.000.934-0.0140.004
call20.000.000.050.030.1033,0530.000.371-0.0130.012
call22.500.000.050.050.5121140.000.070-0.0120.004
call25.000.000.050.030.81827.000.000.048-0.0140.003
call30.000.000.050.001.2980.000.000.033-0.0160.002
call35.000.000.050.001.6760.000.000.026-0.0170.002
put2.500.000.050.006.2090.000.00-0.005-0.0160.001
put5.000.000.050.054.13314.000.00-0.009-0.0160.001
put7.500.000.050.052.97326.000.00-0.013-0.0160.001
put10.000.000.050.042.16030.001.00-0.017-0.0150.001
put12.500.000.050.051.52517.000.00-0.025-0.0140.002
put15.000.000.050.051.0352450.00-0.037-0.0140.002
put17.500.000.050.050.5172,4270.00-0.066-0.0110.004
put20.000.000.500.300.3911000.00-0.607-0.0140.012
put22.500.604.902.832.6380.000.00-0.930-0.0100.004
put25.002.707.500.003.1870.000.00-0.952-0.0120.003
put30.007.5012.500.004.0310.000.00-0.967-0.0140.002
put35.0012.7017.500.004.6390.000.00-0.974-0.0140.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13GSEC
2026-10-19DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-19DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-198-KCurrent report2026-10-18SEC
2026-10-13SCHEDULE 13G/ASEC
2026-10-13SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13D/ASEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-128-KCurrent report2026-08-10SEC
2026-08-12424B5SEC
2026-08-11S-3MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-3SEC
2026-08-10424B5SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-168-K/A2026-07-10SEC
2026-07-08SCHEDULE 13D/ASEC
2026-07-074Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-05-27EFFECTEffectiveness filing by commission orderSEC
2026-05-27424B5SEC
2026-05-22CORRESPSEC
2026-05-22UPLOADUpload SubmissionSEC
2026-05-188-KCurrent report2026-05-18SEC
2026-05-18S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC7.58%
Siren, L.L.C.7.01%
TCG Crossover Management, LLC6.42%
Nantahala Capital Management, LLC5.70%
Redmile Group, LLC4.58%
CITADEL ADVISORS LLC2.81%
Nextech Invest Ltd.2.02%
MILLENNIUM MANAGEMENT LLC1.93%
Ikarian Capital, LLC1.76%
Tetragon Partners GP Ltd1.62%

Funds

Fund% owned
Select Biotechnology Portfolio3.29%
Fidelity Advisor Biotechnology Fund1.02%
Select Health Care Portfolio0.80%
iShares Biotechnology ETF0.39%
ALGER SMALL CAP GROWTH FUND0.22%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND0.09%
Fidelity Nasdaq Composite Index Fund0.03%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF0.02%
ActivePassive International Equity ETF0.01%
Steward Values Enhanced International Fund0.01%

OakChart. SLN. Cached 15 minutes.

Some panels did not load: insider.